Exosome-guided bone targeted delivery of Antagomir-188 as an anabolic therapy for bone loss

• DOI: 10.1016/j.bioactmat.2021.02.014
• Publication Date: 2021-02-23T23:23:34Z
• Authors: Yan Hu; Xiaoqun Li; Qin Zhang; Zhengrong Gu; Ying Luo; Jiawei Guo; Xiuhui Wang; Yingying Jing; Xiao Chen; Jiacan Su
• Keywords: Homing (biology); Exosome

The differentiation shift from osteogenesis to adipogenesis of bone marrow mesenchymal stem cells (BMSCs) characterizes many pathological loss conditions. Stromal cell-derived factor-1 (SDF1) is highly enriched in the for C-X-C motif chemokine receptor 4 (CXCR4)-positive hematopoietic cell (HSC) homing and tumor metastasis. In this study, we displayed CXCR4 on surface exosomes derived genetically engineered NIH-3T3 cells. CXCR4+ selectively accumulated marrow. Then, fused with liposomes carrying antagomir-188 produce hybrid nanoparticles (NPs). NPs specifically gathered released antagomir-188, which promoted inhibited BMSCs thereby reversed age-related trabecular decreased cortical porosity mice. Taken together, study presents a novel way obtain bone-targeted via display promising anabolic therapeutic approach loss.